Cooke T G, Stanton P D, Winstanley J, Murray G D, Croton R, Holt S, George W D
University Department of Surgery, Royal Infirmary, Glasgow, U.K.
Eur J Cancer. 1992;28(2-3):424-6. doi: 10.1016/s0959-8049(05)80067-x.
Tumour growth rates, as measured by incorporation of tritiated thymidine, have been reported as being of prognostic importance in breast cancer. We have measured the thymidine labelling index (TLI) of 185 early breast cancers, followed-up for a minimum of 8 years. Above median TLI was associated with higher tumour grade, but not with other prognostic factors. TLI was not predictive of survival in either univariate or multivariate analysis. The inter- and intra-observer reproducibilities of TLI measurements were poor, which may be a factor limiting its usefulness as a prognostic indicator in breast cancer.
通过氚标记胸腺嘧啶核苷掺入法测得的肿瘤生长速率，据报道在乳腺癌中具有预后重要性。我们测定了185例早期乳腺癌的胸腺嘧啶核苷标记指数（TLI），并对其进行了至少8年的随访。TLI高于中位数与更高的肿瘤分级相关，但与其他预后因素无关。在单因素和多因素分析中，TLI均不能预测生存情况。TLI测量的观察者间和观察者内重复性较差，这可能是限制其作为乳腺癌预后指标实用性的一个因素。
